Robert E. Gerszten, MD, is director of Clinical and Translational Research for the MGH Heart Center. He is an Associate Professor of Medicine (Cardiology) at the Massachusetts General Hospital (MGH) and Harvard Medical School and a Senior Associate Member of the Broad Institute. Dr. Gerszten graduated from Johns Hopkins University School of Medicine, did his residency at the University of Pennsylvania, and his clinical fellowship in Cardiology at MGH. He performed research fellowships at the Cardiovascular Research Institute at UCSF, and the Cardiovascular Research Center (CVRC), MGH. Over the past decade the Gerszten laboratory has built a nationally recognized program in translational research, integrating emerging metabolomic and proteomic approaches towards the identification of novel disease pathways and biomarkers. He is currently the lead PI of an NHLBI Proteomics Center and an Established Investigator of the American Heart Association. Within the MGH, he plays a leadership role on the Executive Committee on Research (ECOR). Dr. Gerszten is an active clinician and serves as a mentor to many of our junior staff.
Dr. Gerszten's clinical interests span the spectrum of general adult consultative cardiology. As Director of Clinical and Translational Research for the MGH Heart Center, he has a particular interest in the application of emerging genomic technologies for early disease prediction and diagnosis, towards the ultimate goal of personalized medicine.
TJ, La Wang, TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. Nature Medicine. 2011 Mar 20. [Epub ahead of print] PMID:21423183
Lewis GD, Farrell L, Wood MJ, Martinovic M, Arany Z, Rowe GC, Souza A, Cheng S, McCabe EL, Yang E, Shi X, Deo R, Roth FP, Asnani A, Rhee EP, Systrom DM, Semigran MJ, Vasan RS, Carr SA, Wang TJ, Sabatine MS, Clish CB, Gerszten RE. Metabolic signatures of exercise in human plasma. Science Translational Medicine 2010 May 26;2(33):33ra37.PMID: 20505214
Study of 'planned' heart attacks identifies markers that could improve treatment, save lives.
ESTABLISHED IN 2011 by ECOR and the MGH Research Advisory Council, the MGH Research Scholars program provides five years of unrestricted funding to give innovative investigators the flexibility to pursue projects that may lead in unexpected directions. Supported by philanthropic gifts, the program expanded from the first group of five recipients to eight scholars in 2012.
A study, led by Robert Gerszten, MD, director of clinical and translational research at the Massachusetts General Hospital Corrigan Minehan Heart Center, identifies a biomarker that could predict the onset of Type 2 diabetes up to 12 years in advance.
A study led by Robert Gerszten, MD, director of clinical and translational research at the Massachusetts General Hospital Institute for Heart, Vascular and Stroke Care, identifies a biomarker that can predict diabetes risk.
Massachusetts General Hospital Cardiology Grand Rounds take place on Wednesdays from 8:00 am to 9:00 am in the O’Keeffe Auditorium of the Blake Building.
Using a system that analyzes blood samples with unprecedented detail, a team led by MGH researchers has developed the first "chemical snapshot" of the metabolic effects of exercise.
Measuring the levels of small molecules in the blood may be able to identify individuals at elevated risk of developing type 2 diabetes as much as a decade before symptoms of the disorder appear.
Researchers at the Massachusetts General Hospital Institute for Heart, Vascular and Stroke Care and Vanderbilt Heart and Vascular Institute have found a chemical biomarker in blood that can predict diabetes risk more than a decade before the onset of the disease.
Phone 2: 617-724-8322